

Joshua M Lang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2846943/publications.pdf>

Version: 2024-02-01

51
papers

1,567
citations

430442

18
h-index

329751

37
g-index

52
all docs

52
docs citations

52
times ranked

2657
citing authors

#	ARTICLE	IF	CITATIONS
1	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020, 52, 778-789.	9.4	198
2	Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents. <i>Frontiers in Immunology</i> , 2015, 6, 29.	2.2	139
3	Pilot trial of interleukin-2 and zoledronic acid to augment CD8 ⁺ T cells as treatment for patients with refractory renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1447-1460.	2.0	127
4	Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. <i>Clinical Cancer Research</i> , 2017, 23, 4704-4715.	3.2	117
5	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. <i>European Urology</i> , 2018, 73, 715-723.	0.9	105
6	A role for microfluidic systems in precision medicine. <i>Nature Communications</i> , 2022, 13, .	5.8	63
7	The VeriFAST: an integrated method for cell isolation and extracellular/intracellular staining. <i>Lab on A Chip</i> , 2013, 13, 391-396.	3.1	60
8	High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1. <i>PLoS ONE</i> , 2016, 11, e0159397.	1.1	54
9	Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation. <i>Clinical Cancer Research</i> , 2017, 23, 746-756.	3.2	52
10	Circulating Tumor Cells: Getting More from Less. <i>Science Translational Medicine</i> , 2012, 4, 141ps13.	5.8	50
11	A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells. <i>Methods</i> , 2013, 64, 137-143.	1.9	45
12	Selective Nucleic Acid Removal via Exclusion (SNARE): Capturing mRNA and DNA from a Single Sample. <i>Analytical Chemistry</i> , 2013, 85, 9764-9770.	3.2	37
13	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2926-2937.	0.8	36
14	Rapid translation of circulating tumor cell biomarkers into clinical practice: technology development, clinical needs and regulatory requirements. <i>Lab on A Chip</i> , 2014, 14, 24-31.	3.1	29
15	BAF155 methylation drives metastasis by hijacking super-enhancers and subverting anti-tumor immunity. <i>Nucleic Acids Research</i> , 2021, 49, 12211-12233.	6.5	29
16	Exclusive Liquid Repellency: An Open Multi-Liquid-Phase Technology for Rare Cell Culture and Single-Cell Processing. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 17065-17070.	4.0	28
17	Paired diagnostic and pharmacodynamic analysis of rare non-small cell lung cancer cells enabled by the VeriFAST platform. <i>Lab on A Chip</i> , 2014, 14, 99-105.	3.1	26
18	Surface topography and hydrophilicity regulate macrophage phenotype in milled microfluidic systems. <i>Lab on A Chip</i> , 2018, 18, 3011-3017.	3.1	25

#	ARTICLE	IF	CITATIONS
19	Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. <i>Journal of Urology</i> , 2018, 199, 1494-1501.	0.2	21
20	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 1644.	3.4	21
21	Integration of Magnetic Bead-Based Cell Selection into Complex Isolations. <i>ACS Omega</i> , 2018, 3, 3908-3917.	1.6	19
22	Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)., 2022, 10, e004198.		19
23	Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board. <i>JCO Precision Oncology</i> , 2017, 1, 1-10.	1.5	18
24	Regulation of inside-out β 1-integrin activation by CDCP1. <i>Oncogene</i> , 2018, 37, 2817-2836.	2.6	17
25	Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 3610-3619.	3.2	17
26	Inducible expression of cancer-testis antigens in human prostate cancer. <i>Oncotarget</i> , 2016, 7, 84359-84374.	0.8	17
27	Versatile exclusion-based sample preparation platform for integrated rare cell isolation and analyte extraction. <i>Lab on A Chip</i> , 2018, 18, 3446-3458.	3.1	16
28	Automated System for Small-Population Single-Particle Processing Enabled by Exclusive Liquid Repellency. <i>SLAS Technology</i> , 2019, 24, 535-542.	1.0	16
29	Exploring Spatial-Temporal Changes in ¹⁸ F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. <i>Journal of Clinical Oncology</i> , 2020, 38, 3662-3671.	0.8	16
30	Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma. <i>Molecular Oncology</i> , 2021, 15, 2330-2344.	2.1	14
31	Prioritization of cancer antigens: keeping the target in sight. <i>Expert Review of Vaccines</i> , 2009, 8, 1657-1661.	2.0	13
32	Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma. <i>Clinical Medicine Insights: Oncology</i> , 2010, 4, CMO.S4088.	0.6	12
33	Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3633-3641.	0.8	12
34	A Randomized Phase II Trial Evaluating Different Schedules of Zoledronic Acid on Bone Mineral Density in Patients With Prostate Cancer Beginning Androgen Deprivation Therapy. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 407-415.	0.9	11
35	Centrosome amplification is a frequent event in circulating tumor cells from subjects with metastatic breast cancer. <i>Molecular Oncology</i> , 2020, 14, 1898-1909.	2.1	11
36	Live cell molecular analysis of primary prostate cancer organoids identifies persistent androgen receptor signaling. <i>Medical Oncology</i> , 2021, 38, 135.	1.2	11

#	ARTICLE	IF	CITATIONS
37	Centrifugation-Assisted Immiscible Fluid Filtration for Dual-Bioanalyte Extraction. <i>Analytical Chemistry</i> , 2019, 91, 11848-11855.	3.2	10
38	Pairing Microwell Arrays with an Affordable, Semiautomated Single-Cell Aspirator for the Interrogation of Circulating Tumor Cell Heterogeneity. <i>SLAS Technology</i> , 2020, 25, 162-176.	1.0	10
39	Volumeless reagent delivery: a liquid handling method for adding reagents to microscale droplets without increasing volume. <i>Lab on A Chip</i> , 2022, 22, 286-295.	3.1	8
40	Development and translation of novel therapeutics targeting tumor-associated macrophages. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 556-562.	0.8	7
41	Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. <i>Urology</i> , 2017, 100, 139-144.	0.5	5
42	Vital ex vivo tissue labeling and pathology-guided micropunching to characterize cellular heterogeneity in the tissue microenvironment. <i>BioTechniques</i> , 2018, 64, 13-19.	0.8	5
43	AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer. <i>Endocrine-Related Cancer</i> , 2021, 28, 645-655.	1.6	5
44	Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies. <i>Immunotherapy</i> , 2013, 5, 1243-1254.	1.0	4
45	Mri-based cancer lesion analysis with 3d printed patient specific prostate cutting guides. <i>American Journal of Clinical and Experimental Urology</i> , 2019, 7, 215-222.	0.4	3
46	SEEMLIS: a flexible semi-automated method for enrichment of methylated DNA from low-input samples. <i>Clinical Epigenetics</i> , 2022, 14, 37.	1.8	3
47	Are liquid biopsies ready for primetime?. <i>Cancer</i> , 2019, 125, 834-837.	2.0	2
48	Fresh tissue procurement and preparation for multicompartement and multimodal analysis of the prostate tumor microenvironment. <i>Prostate</i> , 2022, 82, 836-849.	1.2	2
49	Understanding dynamic interactions in the prostate tumor microenvironment. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 532-534.	0.8	1
50	Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer. <i>Biomarker Research</i> , 2022, 10, 26.	2.8	1
51	Reply to M. K. Bos et al. <i>Journal of Clinical Oncology</i> , 2022, 40, 520-522.	0.8	0